Results for tag: "Lung Fibrosis Drug"

The Lung Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat lung fibrosis, a condition characterized by the thickening and scarring of lung tissue. These drugs are used to reduce inflammation, improve breathing, and slow the progression of the disease. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. The Lung Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include GlaxoSmithKline, Boehringer Ingelheim, Novartis, and AstraZeneca. Other companies, such as Sanofi, Merck, and Pfizer, are also active in the market. Show Less Read more